繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-6

MB-6

Indication
Acting as Adjuvant for metastatic colorectal cancer
Product Advantages
reducing chemo-associated toxicity and enhancing efficacy of chemotherapy
Status
Phase III clinical trial is in progress
Competitive Edge
Oral capsule botanical drug, high safety, not much similar drugs currently on the market or under development
Potential Market
The analysis by GBI Research points out that the market value of colorectal cancer treatment will increase from 8.3 billion U.S. dollars in 2013 to 9.4 billion U.S. dollars in 2020
  • A series of preclinical studies had demonstrated that MB-6 reduced the incidence of colonic polyps and formation of tumor, prolonged survival rate as compared to chemotherapy alone when MB-6 was given together with 5-FU in colorectal cancer bearing mice.
  • MB-6 obtained USFDA and Taiwan Ministry of Health and Welfare (MOHW) phase II IND approval. In the Phase II clinical trials of patients with colorectal cancer in Taiwan, the combination of MB-6 and FOLFOX-4 standard treatment significantly prolonged progression-free survival (PFS) and overall survival, improved chemotherapeutic compliance, and improved FOLFOX-4-induced Neutropenia and reduce the dose of granulocyte colony stimulating factor (G-CSF) used

Phase II clinical trial


体彩p5中奖新闻 云南11选五5最大遗漏查询 股票涨跌是人为控制吗 2013上证指数历史数据 山西十一选五开奖查询 青海快3最近开奖 深圳风采2010103 急速赛车游戏 天津11选5开奖结果查询结果 医药类股票推荐 吉林快三形态 走势图